You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

À propos des lignes directrices

Displaying Guidelines

17 articles

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Document Status: Current
ID: GL-END-C50-35

Aug 2023

Cancer Care Ontario Thyroid Cancer Guideline: An Endorsement of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Document Status: Current
ID: GL END 5-13
Version: N/A

Jun 2023

Cannabis and cannabinoids: Cancer risk and use to manage cancer symptoms

Document Status: Current
ID: N/A
Version: 2

Jan 2023

Consensus-based organizational guideline for the planning and delivery of spine stereotactic body radiotherapy treatment in Ontario

Document Status: Current
ID: GL 21-6

Apr 2023

Consensus Pathology Recommendations for Mesenchymal Tumours of Soft Tissue and Bone

Document Status: Current
Version: 1.0

Mar 2023

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2022

Document Status: Current
ID: PET 2022-1

Jan 2023

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

Document Status: Current
ID: PET 2023-1

Nov 2023

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2022

Document Status: Current
ID: PET 2022-2

Jun 2023

Management of Early-Stage Hodgkin Lymphoma

Document Status: Current
ID: GL 6-20
Version: 2

May 2023

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Document Status: Current
ID: GL-END 3-25

Nov 2023

Optimizing Ambulatory Systemic Treatment Models of Care

Document Status: Current
Version: 1

Jul 2023

Patient Safety Issues: Key Components of Intravenous Systemic Cancer Therapy Labelling

Document Status: Current
ID: 12-11
Version: 2

Apr 2023